Drugs / SARS-CoV-2 Inactivated Vaccine
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT04884685 | May → Aug 2021 | COVID-19 | Sinovac Life Sciences Co., Ltd. | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT05079217 | Dec 2021 | COVID-19 | Sinovac Biotech Co., Ltd | Unknown | No outcome recorded |
| Phase 4 | NCT04992208 | Jul 2021 → Mar 2023 | COVID-19 | Sinovac Life Sciences Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT04962308 | Jun → Aug 2021 | COVID-19 | Sinovac Research and Development Co., Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT04911790 | Jun 2021 → Jan 2023 | COVID-19 | Sinovac Research and Development Co., Ltd. | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT05228613 Comparator | Feb → Aug 2022 | COVID-19 | PT Bio Farma | Completed | No outcome recorded |
| Phase 1 | NCT05067894 Comparator | Dec 2021 → Apr 2022 | COVID-19 | PT Bio Farma | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SARS-CoV-2 Inactivated Vaccine | “SARS-CoV-2 Inactivated Vaccine 1200SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection” NCT05079217 ↗6“SARS-CoV-2 Inactivated Vaccine 600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection” NCT04992208 ↗ “SARS-CoV-2 Inactivated Vaccine 600SU inactivated virus in 0·5 mL of aluminiumhydroxide solution per injection” NCT04911790 ↗ |
| Modality | Vaccine | “inactivated SARS-CoV-2 vaccine” NCT04884685 ↗ |
| Route | Intramuscular | “Vaccine will given by intramuscular injection” NCT04884685 ↗ |